What on earth is going on with the AstraZeneca share price?

The AstraZeneca share price has fallen 30% from its peak in August. Dr James Fox explains what’s going on with this FTSE 100 behemoth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE:AZN) share price just dipped below £100 per share. The stock has seriously underperformed in recent months, falling from above £130 in August.

So, let’s take a look at what’s being going on and explore whether investors are looking at an opportunity to buy stock in this British pharma giant.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

China controversy

AstraZeneca’s shares slumped in early November following reports of an expanding insurance fraud investigation in China involving numerous senior executives.

Should you invest £1,000 in Associated British Foods right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Associated British Foods made the list?

See the 6 stocks

The probe, described as the largest insurance fraud case in China’s pharmaceutical sector in recent years, has implicated dozens of AstraZeneca staff, including China President Leon Wang.

The investigation has broadened to include various Chinese authorities, raising concerns about the company’s operations in its second-largest revenue market.

AstraZeneca has stated that it will cooperate with Chinese authorities, but hasn’t commented on the allegations.

Targets under scrutiny

The news has sparked worries about the stability of AstraZeneca’s sales in China, potentially impacting its goal of reaching $80bn in global revenue by 2030.

China contributed around 13% of total revenue in 2023 — AstraZeneca’s largest market is the US, followed by China, with Europe rounding out the top three.

Moreover, the country’s large population and expanding healthcare sector offer substantial opportunities for AstraZeneca’s oncology, biopharmaceuticals, and rare disease portfolios. It’s a central growth market as AstraZeneca looks to transform revenues, which stood at $45.8bn in 2023.

To achieve its revenue target, AstraZeneca plans to launch 20 new medicines by 2030, many of which have the potential to generate over $5bn in peak-year revenue. 

The company’s strategy involves developing treatments for at least half of all potential cancer types and pursuing alternatives to traditional treatments like chemotherapy and radiation.

The Trump effect

While the broad movement has been downwards, AstraZeneca stock pushed slightly higher after Donald Trump’s election victory. While I’ve read some mixed opinions, it appears his win is seen as modestly positive for the pharmaceutical industry, including AstraZeneca.

For one, his administration is likely to be more accommodating to mergers and acquisitions, potentially deprioritising the Inflation Reduction Act, and adopt a less aggressive stance on drug pricing.

However, uncertainty remains regarding FDA independence and the potential influence of anti-vaxxer Robert F. Kennedy Jr. on healthcare policy. In fact, as I write, a number of articles have just been published noting widespread concern about Kennedy.

The bottom line

It’s fair to say that there’s a lot going on which isn’t related to earnings or drug development. That’s going to make one of the most expensive stocks on the FTSE 100 pretty volatile.

However, pushing through the noise, the current forecasts and valuation data looks pretty strong. Sales are expected to rise to $52bn this year and earnings are forecasted to shoot up to £5.50 per share (up from £3.81).

In turn, this means the stock is trading around 23 times forward earnings, a figure that falls to 19.2 times and 17 times in 2025 and 2026 respectively.

I think it’s worthwhile being wary of the impact of this China investigation, while recognising that this could be a rare chance to pick up AstraZeneca stock on the cheap.

Personally, I’ve owned AstraZeneca shares for a while, but may hold back on buying more for the time being. Let’s see how things pan out.

Should you buy Associated British Foods now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Investing Articles

At a 52-week low but forecast to rise 73%! Is this growth share the FTSE’s top recovery play? 

This FTSE 100 growth share has taken an absolute beating over the past two years but Harvey Jones says the…

Read more »

Investing Articles

This FTSE 250 share offers a juicy 9.8% yield. Will it last?

This well-known FTSE 250 share has a percentage dividend yield approaching double digits. Should Christopher Ruane add the income share…

Read more »

Investing Articles

Is a £333,000 portfolio enough to retire and live off passive income?

A third of a million pounds can generate a serious amount of passive income, but relying on this sum alone…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing For Beginners

Why FTSE 100 investors should pay attention to ‘Liberation Day’

Jon Smith explains why the upcoming tariff announcement from across the pond could have an impact on the FTSE 100,…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s why Nvidia stock fell 13% in March

The Nvidia stock price rise was looking unstoppable. Should investors now be wondering if the same might be true of…

Read more »

US Stock

It’s ISA deadline week! Here’s my 3-step game plan

Jon Smith tries to calm the hype around the last minute ISA rush to buy stocks and explains why he's…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£10,000 invested in BAE Systems shares at Christmas is now worth…

BAE Systems shares have been surging in the FTSE 100 in 2025, driven higher by the wavering US commitment to…

Read more »

Investing Articles

Up 19% in 2 weeks, can the Tesla share price rebound further?

Tesla's first-quarter delivery numbers came out today. Will they help persuade our writer to invest his money at the current…

Read more »